• 1
    Tisdale MJ. Protein loss in cancer cachexia. Science 2000; 289: 22934.
  • 2
    Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, Cohen MH, Douglass HO Jr, Engstrom PF, Ezdinli EZ, Horton J, Johnson GJ, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 1980; 69: 4917.
  • 3
    Puccio M, Nathanson L. The cancer cachexia syndrome. Semin Oncol 1997; 24: 27787.
  • 4
    Argiles JM, Alvarez B, Lopez-Soriano FJ. The metabolic basis of cancer cachexia. Med Res Rev 1997; 17: 47798.
  • 5
    Cipriano SC, Chen L, Kumar TR, Matzuk MM. Follistatin is a modulator of gonadal tumor progression and the activin-induced wasting syndrome in inhibin-deficient mice. Endocrinology 2000; 141: 231927.
  • 6
    Hirai K, Hussey HJ, Barber MD, Price SA, Tisdale MJ. Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients. Cancer Res 1998; 58: 235965.
  • 7
    Onuma E, Sato K, Saito H, Tsunenari, T, Ishii K, Esaki K, Yabuta N, Wakahara Y, Yamada-Okabe H, Ogata E. Generation of a humanized monoclonal antibody against human parathyroid hormone–related protein and its efficacy against humoral hypercalcemia of malignancy. Anticancer Res 2004; 24: 266574.
  • 8
    Iguchi H, Onuma E, Sato K, Sato Ka, Ogata E. Involvement of parathyroid hormone–related protein in experimental cachexia induced by a human lung cancer–derived cell line established from a bone metastasis specimen. Int J Cancer 2001; 94: 247.
  • 9
    Pollock JH, Blaha MJ, Lavish SA, Stevenson S, Greenfield EM. In vivo demonstration that parathyroid hormone and parathyroid hormone–related protein stimulate expression by osteoblasts of interleukin-6 and leukemia inhibitory factor. J Bone Miner Res 1996; 11: 7549.
  • 10
    Takahashi S, Hakuta M, Aiba K, Ito Y, Horikoshi N, Miura M, Hatake K, Ogata E. Elevation of circulating plasma cytokines in cancer patients with high plasma parathyroid hormone-related protein levels. Endocr Relat Cancer 2003; 10: 4037.
  • 11
    Ikeda K, Matsumoto T, Fukumoto S. A hypercalcemic nude rat model that completely mimics human syndrome of humoral hypercalcemia of malignancy. Calcif Tissue Int 1988; 43: 97102.
  • 12
    Suzuki T, Abe S, Yamaguchi M, Baba A, Hori T, Shiraishi H, Ito T. Effects of cocaine administration on receptor binding and subunits mRNA of GABAa-benzodiazepine receptor complexes. Synapse 2000; 38: 198215.
  • 13
    Ogata E. Parathyroid hormone–related protein as a potential target of therapy for cancer-associated morbidity. Cancer 2000; 88: 290911.
  • 14
    Fleisch H. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 1991; 42: 91944.
  • 15
    Okada M, Noguchi S, Hasegawa Y, Inukai T. Effect of pamidronete in a rat hypercalcemia model induced by cholecalciferol. Arzneimittelforschung 1992; 42: 5436.
  • 16
    Capparelli C, Kostenuik PJ, Morony S, Starnes C, Weimann B, Van G, Scully S, Qi M, Lacey DL, Dunstan CR. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Res 2000; 60: 7837.
  • 17
    Strassmann G, Fong M, Kenney JS, Jacob CO. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 1992; 89: 16814.
  • 18
    Fujita J, Tsujinaka T, Yano M, Ebisui C, Saito H, Katsume A, Akamatsu K, Ohsugi Y, Shiozaki H, Monden M. Anti-interleukin-6 receptor antibody prevents muscle atrophy in Colon26 adenocarcinoma-bearing mice with modulation of lysosomal and ATP-ubiquitin-dependent proteolytic pathways. Int J Cancer 1996; 68: 63743.
  • 19
    Yoneda T, Nakai M, Moriyama K, Scott L, Ida N, Kunitomo T, Mundy GR. Neutralizing antibodies to human interleukin 6 reverse hypercalcemia associated with a human squamous carcinoma. Cancer Res 1993; 53: 73740.
  • 20
    Tamura S, Ouchi KF, Mori K, Endo M, Matsumoto T, Eda H, Tanaka Y, Ishitsuka H, Tokita H, Yamaguchi K. Involvement of human interleukin 6 in experimental cachexia induced by a human uterine cervical carcinoma xenograft. Clin Cancer Res 1995; 1: 13538.
  • 21
    Rothe L, Collin-Osdoby P, Chen Y, Sunyer T, Chaudhary L, Tsay A, Goldring S, Avioli L, Osdoby P. Human osteoclasts and osteoclast-like cells synthesize and release high basal and inflammatory stimulated levels of the potent chemokine interleukin-8. Endocrinology 1998; 139: 435363.
  • 22
    Uy HL, Mundy GR, Boyce BF, Story BM, Dunstan CR, Yin JJ, Roodman GD, Guise TA. Tumor necrosis factor enhances parathyroid hormone–related protein–induced hypercalcemia and bone resorption without inhibiting bone formation in vivo. Cancer Res 1997; 57: 31949.